Abstract:Protease activated receptor 4 (PAR4) is an important target in antiplatelet therapy to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth, while retaining initial thrombus formation, by acting on the late diffusion stage of platelet aggregation, and may provide a safer alternative to other antiplatelet agents. To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly selective PAR4 antagonists with nanomolar potency on human platelets. Of these, 13 and 30g, with an 8-benzo[d]thiazol-2-yl-substituted quinazolin-4(3H)-one structure, showed optimal activity (h. PAR4-AP PRP IC50 = 19.6 nM and 6.59 nM, respectively) on human platelets. Furthermore, 13 and 30g showed excellent selectivity for PAR4 versus PAR1 and other receptors (IC50s > 10 μM) on human platelets. And 13 and 30g were lack of cross-reactivity for PAR1 or PAR2 (PAR1 AP FLIPR IC50 > 3162 nM, PAR2 AP FLIPR IC50 > 1000 nM) in the calcium mobilization assays. Metabolic stability assays and cytotoxicity tests of 13 and 30g indicated that these compounds could sever as promising drug candidates for the development of novel PAR4 antagonists. In summary, the quinazolin-4(3H)-one-based analogues are the first reported chemotypes with excellent activity and selectivity against PAR4, and, in the current study, we expanded the structural diversity of PAR4 antagonists. The two compounds, 13 and 30g, found in our study could be promising starting points with great potential for further research in antiplatelet therapy.

Discovery of Potent Orally Active Protease-Activated Receptor 1 (par1) Antagonists Based on Andrographolide

Synthesis and Evaluation of Novel and Potent Protease Activated Receptor 4 (PAR4) Antagonists Based on a Quinazolin-4(3H)-one Scaffold.

Discovery of quinazoline-benzothiazole derivatives as novel potent protease-activated receptor 4 antagonists with improved pharmacokinetics and low bleeding liability

Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis

Identification of Poly(adp-Ribose)polymerase 1 and 2 (PARP1/2) As Targets of Andrographolide Using an Integrated Chemical Biology Approach.

Discovery of 2,3-Dihydro[1,4]dioxino[2,3- g ]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity and Low Bleeding Tendency

Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents

Research progress on thrombin receptorantagonists

A label-free screening approach targeted protease-activated receptor 1 based on dynamic mass redistribution in living cells

Synthesis of 3,15-Disuccinate-12-coumarin Substituted Andrographolide Derivatives and Their Antiplatelet Aggregation Activities in Vitro

Synthesis and Antiplatelet Activity of Ethyl 4-(1-benzyl-1h-indazol-3-yl)benzoate (YD-3) Derivatives.

Design, Synthesis and Evaluation of Novel 2-Amino-3-(naphth-2-yl)propanoic Acid Derivatives As Potent Inhibitors of Platelet Aggregation

Inhibitors of Protease-Activated Receptor 4 (PAR4): a Review of Recent Patents (2013-2021).

Discovery of 7, 4-dimethoxy-3-hydroxyflavone as a protease-activated receptor 4 antagonist with antithrombotic activity and less bleeding tendency in mice

Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021)

Synthesis and antiplatelet aggregation activities of prasugrel derivatives

A Novel Protease-Activated Receptor 1 Inhibitor from the Leech Whitmania Pigra.

Design, Synthesis of Novel Tryptophan Derivatives for Antiplatelet Aggregation Activity Based on Tripeptide Penw (Pglu-Asn-trp)

Design and Synthesis of Benzo-Spirocyclic Derivatives as Potent PARP-1 Inhibitors

Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1h-indol-2-yl)methanols As Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against Γ-Thrombin.

Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog